MannKind did it: Afrezza inhaled insulin OK'd
This article was originally published in Scrip
After an initial panic, likely over postmarketing requirements, investors on 27 June managed to catch their collective breath and rally around shares of MannKind, which pulled off a win from the FDA for the firm's rapid-acting inhaled insulin Afrezza (insulin human [rDNA origin]) to improve glycemic control in patients with type 1 and type 2 diabetes – something Wall Street had long predicted would be impossible.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.